| Anti-hepatitis C virus drugs in development. | |
| | |
MedLine Citation:
|
PMID: 22537441 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Development of robust cell culture models for hepatitis C viral infection has greatly increased our understanding of this virus and its life cycle. This knowledge has led to the development of many drugs that target specific elements of viral replication, including viral proteins and host factors required for replication. The NS3/4A serine protease inhibitors were the first of these to be used in the clinic, and reagents that target other elements of the viral lifecycle are in advanced stages of clinical development. These include new NS3/4A protease inhibitors, NS5B RNA-dependent RNA polymerase inhibitors, NS5A inhibitors, and host-directed antivirals, such as cyclophilin inhibitors. Alternative interferons with possibly improved tolerability, specifically interferon-λ1 (interleukin-29), are also under development. These new reagents against hepatitis C virus should lead to highly effective, well-tolerated, and likely interferon-sparing therapies in the next several years. |
| | |
Authors:
|
Esperance A K Schaefer; Raymond T Chung |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Gastroenterology Volume: 142 ISSN: 1528-0012 ISO Abbreviation: Gastroenterology Publication Date: 2012 May |
Date Detail:
|
Created Date: 2012-04-27 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0374630 Medline TA: Gastroenterology Country: United States |
Other Details:
|
Languages: eng Pagination: 1340-1350.e1 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved. |
Affiliation:
|
Massachusetts General Hospital, Department of Medicine, Gastrointestinal Unit, Boston, Massachusetts. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antiv...
Next Document: Effectiveness of hepatitis B treatment in clinical practice.